{"product_id":"medical-oncology-board-review-course-2017-the-passmachine-videos","title":"Medical Oncology Board Review Course 2017 (The Passmachine) (Videos)","description":"\u003cdiv class=\"prod-title\"\u003e\n\u003ch3\u003eMedical Oncology Board Review Course 2017 (The Passmachine) (Videos)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod-price\"\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cstrong style=\"font-size: 20.16px;color: #333333\"\u003eDescription:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv id=\"tab-description\" class=\"woocommerce-Tabs-panel woocommerce-Tabs-panel--description panel entry-content active\" role=\"tabpanel\" aria-labelledby=\"tab-title-description\"\u003e\n\u003cdiv class=\"single-main-content\"\u003e\n\u003cp\u003e\u003cstrong\u003eIntended Audience:\u003c\/strong\u003e Oncologists\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eLearning Objectives: \u003c\/strong\u003e\u003cbr\u003e\nUpon completion of this program, participants should be able to:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAssess diagnosis, staging and prognostic factors of breast cancer.\u003c\/li\u003e\n\u003cli\u003eExplain the different types of gynecologic cancer.\u003c\/li\u003e\n\u003cli\u003eDescribe basic pharmacological and biological principles in the management and treatment of cancer.\u003c\/li\u003e\n\u003cli\u003eDevelop comprehensive management and treatment plans for genitourinary cancer including bladder, other urothelial, prostate, and renal cancer, and germ cell tumors.\u003c\/li\u003e\n\u003cli\u003eDemonstrate medical management of lung and thymic cancer and mesothelioma.\u003c\/li\u003e\n\u003cli\u003eIntegrate modalities of care and ethics including treatment-related issues, complications, supportive care, survivorship, psychosocial aspects of cancer, bioethical\/legal\/economic issues, and communication skills.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccreditation Statement:\u003c\/strong\u003e\u003cbr\u003e\nThis activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of PeerPoint Medical Education Institute and American Physician Institute for Advanced Professional Studies, LLC. PeerPoint Medical Education Institute is accredited by the ACCME to sponsor continuing medical education for physicians.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eMOC Accreditation Statement:\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp style=\"padding-left: 40px\"\u003eSuccessful completion of this CME activity enables the participant to earn up to 34.25 MOC points in the American Board of Internal Medicine’s (ABIM®) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM® MOC points.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDesignation Statement:\u003c\/strong\u003e\u003cbr\u003e\n\u003cstrong\u003eOnline Course v4.1, Release Date\u003cspan style=\"color: #ff0000\"\u003e October 15, 2017\u003c\/span\u003e, Termination Date \u003cspan style=\"color: #ff0000\"\u003eOctober 14, 2020\u003c\/span\u003e:\u003c\/strong\u003e\u003cbr\u003e\nThe PeerPoint Medical Education Institute designates this enduring material for a maximum of \u003cstrong\u003e34.25\u003c\/strong\u003e \u003cem\u003eAMA PRA Category 1 Credits\u003c\/em\u003e™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eQuestion Bank, Release Date \u003cspan style=\"color: #ff0000\"\u003eApril 1, 2018\u003c\/span\u003e, Termination Date \u003cspan style=\"color: #ff0000\"\u003eApril 1, 2021\u003c\/span\u003e:\u003c\/strong\u003e\u003cbr\u003e\nThe PeerPoint Medical Education Institute designates this enduring material for a maximum of \u003cstrong\u003e41.75\u003c\/strong\u003e \u003cem\u003eAMA PRA Category 1 Credits\u003c\/em\u003e™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eNurses \u0026amp; Nurse Practitioners:\u003c\/strong\u003e For all your CE requirements for recertification, the ANCC will accept \u003cem\u003eAMA PRA Category 1 Credits\u003c\/em\u003e™ from organizations accredited by the ACCME.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePhysician Assistants:\u003c\/strong\u003e The NCCPA accepts \u003cem\u003eAMA PRA Category 1 Credits\u003c\/em\u003e™ from organizations accredited by the ACCME.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan class=\"lead-text\"\u003eLASER-FOCUSED LECTURES:\u003c\/span\u003e \u003cem\u003eThe Pass Machine\u003c\/em\u003e Medical Oncology board review course will help you master the ABIM\u003csup\u003e®\u003c\/sup\u003e exam material quickly and easily. This course features a comprehensive library of short video lectures that are precisely aligned to the Medical Oncology Certification and Medical Oncology MOC exam blueprints. This way, you’ll focus on all of the exam topics and keywords with no wasted effort.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan class=\"lead-text\"\u003eTHE “QBL” METHOD:\u003c\/span\u003e “Question-Based Learning” ensures that your review is 100% relevant to the ABIM\u003csup\u003e®\u003c\/sup\u003e Medical Oncology exam. This proven method works by pairing multiple choice questions with related lectures, allowing you to review a topic before answering the corresponding question.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cspan class=\"lead-text\"\u003eBOARD-EXPERIENCED FACULTY:\u003c\/span\u003e  The Medical Oncology Certification and Medical Oncology MOC courses feature board-certified faculty experienced in teaching Medical Oncology board exam preparation. Thus, every lecture is up-to-date, medically accurate and entirely board-relevant.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cstrong\u003eTopics\/Speaker:\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003ch5\u003eHematologic Neoplasms\u003c\/h5\u003e\n\u003cdiv class=\"course-title\"\u003eAcute Leukemia and Myelodysplasia (1 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003ePeter Silberstein, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eChronic Myeloid Leukemia and Myeloproliferative Neoplasms (.75 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003ePeter Silberstein, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eChronic Lymphoproliferative Leukemias (.75 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003ePeter Silberstein, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eHodgkin Lymphoma (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003ePeter Silberstein, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eMultiple Myeloma and Plasma Cell Dyscrasias (.75 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003ePeter Silberstein, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eNon-Hodgkin Lymphoma (1.5 Hours)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003ePeter Silberstein, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003ch5\u003eThoracic Cancer\u003c\/h5\u003e\n\u003cdiv class=\"course-title\"\u003eNon-small cell lung cancer (3.25 Hours)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eSridhar Mani, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eSmall Cell Lung Cancer (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eSridhar Mani, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eMesothelioma and Thymus Cancer (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eSridhar Mani, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003ch5\u003eBreast Cancer\u003c\/h5\u003e\n\u003cdiv class=\"course-title\"\u003ePremalignant Conditions and High-Risk Factors (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eLea Baer, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eCarcinoma in Situ (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eLea Baer, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eEarly-Stage Invasive Carcinoma (1.75 Hours)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eLea Baer, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eLocally advanced and inflammatory disease (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eLea Baer, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eLocally Recurrent Disease (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eLea Baer, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eMetastatic Disease (1.5 Hours)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eLea Baer, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eLess Common Histologies and Clinical Scenarios (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eLea Baer, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003ch5\u003eGenitourinary Cancer\u003c\/h5\u003e\n\u003cdiv class=\"course-title\"\u003eGerm Cell Tumors (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eTerence Friedlander, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eProstate Cancer (1.75 Hours)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eTerence Friedlander, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eRenal Cell Cancer (1 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eTerence Friedlander, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eUrothelial and other Genitorourinary cancers (1 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eTerence Friedlander, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003ch5\u003eGynecologic Cancer\u003c\/h5\u003e\n\u003cdiv class=\"course-title\"\u003eCancer of the Cervix, Vulva, and Vagina (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003ePeter Silberstein, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eOvarian, Fallopian Tube, and Primary Peritoneal Cancers (1 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003ePeter Silberstein, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eOther Gynecologic Malignancies (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003ePeter Silberstein, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003ch5\u003eGastrointestinal Cancer\u003c\/h5\u003e\n\u003cdiv class=\"course-title\"\u003eGastrointestinal – Colorectal Cancer (1 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eMichael Morse, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eGastrointestinal – Esophageal and Gastric Cancer (1 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eMichael Morse, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eGastrointestinal – Hepatocellular and Biliary Gallbladder Cancer and Neuroendocrine Tumors (1 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eMichael Morse, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eGastrointestinal – Pancreatic and Anal Cancer (1 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eMichael Morse, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003ch5\u003eSkin Cancer, Sarcomas, and Unknown Primary Site\u003c\/h5\u003e\n\u003cdiv class=\"course-title\"\u003eMelanoma (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eNatalya Mar, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eOther Skin Cancers (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eNatalya Mar, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eBone and Soft-Tissue Sarcomas (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eNatalya Mar, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eUnknown Primary Site (1.25 Hours)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eNatalya Mar, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003ch5\u003eAnticancer Therapeutics, Clinical Research Methodology, and Ethics\u003c\/h5\u003e\n\u003cdiv class=\"course-title\"\u003ePrinciples of Allied Disciplines (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eSridhar Mani, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eAnticancer Therapeutics (3 Hours)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eSridhar Mani, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eClinical Research Methodology and Ethics (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eSridhar Mani, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003ch5\u003eSupportive Care, Survivorship, and Communication\u003c\/h5\u003e\n\u003cdiv class=\"course-title\"\u003eClinical Manifestations of advanced cancer and its treatment (1.5 Hours)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003ePeter Silberstein, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eCancer Pain (.75 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003ePeter Silberstein, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eSurvivorship Issues (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003ePeter Silberstein, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eEnd of Life Issues (.75 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003ePeter Silberstein, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eProcedure-related issues (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003ePeter Silberstein, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003cdiv class=\"course-title\"\u003eCommunication (.25 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003ePeter Silberstein, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003ch5\u003eHead, Neck, Thyroid, and Central Nervous System Malignancies\u003c\/h5\u003e\n\u003cdiv class=\"course-title\"\u003eHead and Neck Cancer, Thyroid Cancer, Salivary Gland (1 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eTanguy Seiwert, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"course-agenda\"\u003e\n\u003ch5\u003eGenetics and Tumor Biology\u003c\/h5\u003e\n\u003cdiv class=\"course-title\"\u003eCancer Biology and Genetics (.5 Hour)\u003c\/div\u003e\n\u003cdiv class=\"faculty-name\"\u003eSridhar Mani, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c\/div\u003e\n","brand":"My Store","offers":[{"title":"Default Title","offer_id":42954665853026,"sku":"MED-AMB07831","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Medical-Oncology-Board-Review-Course-2017-The-Passmachine-Videos.png?v=1779382021","url":"https:\/\/meducourse.com\/products\/medical-oncology-board-review-course-2017-the-passmachine-videos","provider":"Meducourse","version":"1.0","type":"link"}